Fusion Pharmaceuticals Investor Presentation Deck
January 2024, 26 slides
  1. Fusion Pharmaceuticals
  2. Related Decks
  3. Investor Presentation Decks
corporate presentation yee | Fusion Pharmaceuticals
forward looking statements meals | Fusion Pharmaceuticals
fusion is a leader in the space | Fusion Pharmaceuticals
lead program | Fusion Pharmaceuticals
is currently the most advanced actinium based targeted radiotherapy in development | Fusion Pharmaceuticals
target enrollment complete in study data anticipated in | Fusion Pharmaceuticals
fusion aligns with on potential registrational pathway a | Fusion Pharmaceuticals
significant and rapidly growing market in patients expands potential opportunity potential market opportunity i | Fusion Pharmaceuticals
program milestones patients | Fusion Pharmaceuticals
actinium supply manufacturing capabilities | Fusion Pharmaceuticals
alpha emitting radioisotopes represent the future of mela | Fusion Pharmaceuticals
fusion actinium supply designed to provide execution advantage | Fusion Pharmaceuticals
fusion is built on a foundation of manufacturing | Fusion Pharmaceuticals
moving the field beyond prostate and nets fusion clinical stage pipeline | Fusion Pharmaceuticals
unlocking the potential of in cancers outside of the few current approved indications | Fusion Pharmaceuticals
fusion pipeline next generation using lessons from say | Fusion Pharmaceuticals
phase trial a first of its kind antibody based targeted alpha therapy study for solid tumors well established cancer found on parent told antibody to or binding | Fusion Pharmaceuticals
cohort in cold hot dosing regimen showed promising results that supported dose in june fusion reported data from the first cold hot dosing cohort at no limited to transient grade or less thrombocytopenia patients showed stable disease ovarian patient received cycles of therapy dose escalated to | Fusion Pharmaceuticals
encouraging safety and early signals of activity at pet | Fusion Pharmaceuticals
fusion early stage pipeline | Fusion Pharmaceuticals
recognizing the potential of tats as next generation with collaboration | Fusion Pharmaceuticals
a small molecule tat targeting receptor | Fusion Pharmaceuticals
fusion oncology drug development | Fusion Pharmaceuticals
unaudited and milestones extended into | Fusion Pharmaceuticals
fusion is a leader in the space | Fusion Pharmaceuticals
thank you | Fusion Pharmaceuticals
See More
Fusion Pharmaceuticals
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Manufacturing
Tumor
Cancer
Preclinical
Solid tumor
Recent decks by Fusion Pharmaceuticals
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
June 2020
See all presentations by Fusion Pharmaceuticals (4 decks)
Related decks
Nuvalent
Investor Presentation
October 2022
BioNTech
Results
May 2021
Nuvalent
Investor Presentation
August 2023
BioNTech
Results
March 2021
Mink Therapeutics
IPO
October 2021
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Nuvalent
Investor Presentation
May 2023
Recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
June 2020
Nuvalent
Investor Presentation
October 2022
BioNTech
Results
May 2021
Nuvalent
Investor Presentation
August 2023
BioNTech
Results
March 2021
Mink Therapeutics
IPO
October 2021
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Nuvalent
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights